azithromycin for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
ACTION NCT04332107		RCT	azithromycin	placebo	COVID 19 outpatients	some concern	171/92	inconclusive	inconclusive 1 % increase in clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias The original primary outcome was changed given the lower risk of hospitalization and slower than anticipated enrollment.

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis